Ddr

Quick links to important sections

Ddr

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ddr

Ddr is a brand name for a medication containing dexlansoprazole, a type of drug known as a Proton Pump Inhibitor (PPI). Its primary function is to suppress the production of gastric (stomach) acid. Dexlansoprazole works by targeting and inhibiting the (H+/K+)-ATPase enzyme, commonly called the proton pump, found in the stomach's parietal cells. By blocking this final step in the acid production process, the overall acid level in the stomach is significantly reduced.


Uses

Ddr is indicated for the treatment of conditions related to excessive stomach acid. It is used for several conditions, including:

  • Healing Erosive Esophagitis (EE): Treating the damage to the lining of the esophagus caused by acid reflux.
  • Maintenance of Healed EE: Keeping the esophagus healed and relieving associated heartburn.
  • Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD): Providing relief for frequent heartburn symptoms in patients whose GERD has not caused visible erosion of the esophagus.

Dual Delayed Release Formulation

Dexlansoprazole is formulated as a Dual Delayed Release (DDR) capsule. This unique delivery system contains two types of enteric-coated granules with different dissolution rates, resulting in two distinct peaks of medicine concentration in the blood plasma. This design aims to provide sustained acid suppression over a longer period.

Quick Facts

Classification Key Mechanism Indication Examples
Proton Pump Inhibitor (PPI) Blocks the gastric proton pump (H+/K+-ATPase) Erosive Esophagitis, GERD

Ddr capsules are typically swallowed whole and may be taken with or without food.

What side effects are possible with Ddr?

Possible Side Effects and Safety Information

Ddr (containing dexlansoprazole) is an antiulcer medicine belonging to the Proton Pump Inhibitor (PPI) class. The safety profile is based on clinical data and post-marketing surveillance for this class of drug, which is subject to continuous monitoring by regulatory bodies.

Adverse Reaction Scope

Classification Category Regulatory-Based Summary
Key Adverse Reaction Categories Gastrointestinal disturbances, nervous system effects, and respiratory issues.
Frequency Classification Common reactions often include headache, diarrhea, abdominal pain, nausea, and flatulence.
System-Organ Classes Involved Gastrointestinal System, Nervous System, Skin and Subcutaneous Tissue (e.g., rashes).
Serious Adverse Reactions Infrequent but serious risks include Clostridium difficile-associated diarrhea, acute interstitial nephritis, systemic lupus erythematosus (SLE), and severe cutaneous adverse reactions.
Population-Specific Considerations Use in pregnancy is advised with caution; breastfeeding should be discussed with a healthcare professional. Older patients may be at increased risk of certain adverse effects, including bone fracture.
Dose- or Exposure-Related Patterns Long-term and high-dose use of PPIs, like dexlansoprazole, is associated with an increased risk of bone fractures (hip, wrist, spine) and Vitamin B12 deficiency.
Safety-Related Restrictions/Limitations Caution is advised in patients with pre-existing liver impairment. Use should generally be for the shortest duration and lowest effective dose necessary to manage the condition. Avoid concomitant use with certain antiviral drugs (e.g., atazanavir, rilpivirine).

Safety Classifications (High-Level)

Classification Element Regulatory Basis (PPI Class)
Regulatory Frequency Framework Used Typically uses established frameworks (e.g., EMA/ICH frequency bands: Very Common ge 1/10, Common ge 1/100 to <1/10) in labeling.
Regulatory Basis Information compiled from major governmental authority documents (e.g., FDA-approved labeling, EMA Summary of Product Characteristics).
Context-of-Use Safety Notes Warnings often require monitoring for low magnesium levels (hypomagnesemia) and potential risk of Clostridium difficile-associated diarrhea (CDAD) with prolonged use.

Regulatory Safety Summary

  • The most frequently reported adverse reactions are typically mild to moderate gastrointestinal issues and headache.
  • Long-term therapy is officially linked to important safety risks, including an increased risk of bone fracture and B12 deficiency, requiring physician supervision.
  • Discontinuation or caution is necessary if symptoms of severe hypersensitivity, kidney inflammation, or persistent diarrhea develop.

Connection to the overall safety profile: The official safety information establishes that while the drug is generally well-tolerated for short-term use, the overall risk profile is defined by a commonality of mild gastrointestinal and nervous system effects. The most clinically significant risks are rare, but include serious infections and long-term, dose-related systemic effects that necessitate specific monitoring and restrictions, particularly concerning duration of therapy and use in vulnerable populations.

Overdose and Emergency Response

Regulatory documentation specifies the clinical findings and required emergency response in cases of dexlansoprazole overdose. Any suspected overdose event requires individuals to seek immediate medical attention.

Documented Overdose Manifestations

The official prescribing information cites specific reactions associated with high-dose ingestion. Hypertension has been documented as a serious adverse event in high-dose scenarios reviewed by regulatory bodies. Non-serious adverse reactions reported under these conditions include hot flashes, contusion, oropharyngeal pain, and weight loss.

Regulatory Findings and Management

Regulatory studies of high-dose exposures, including single ingestions up to 300 mg and multiple daily doses of 120 mg, have been formally noted by authorities as not resulting in death or other severe adverse events. This finding establishes a regulatory baseline for potential severity.

Management in an overdose context is defined as symptomatic and supportive, as no specific antidote is known for dexlansoprazole. Furthermore, the regulatory context notes that dexlansoprazole is not expected to be removed from the circulation by hemodialysis. Urgent medical attention is the mandated course of action to ensure clinical monitoring and appropriate supportive care for any documented adverse symptoms.

Therapeutic Uses of Ddr

What Darunavir Treats: Main Uses and Benefits

Darunavir is used in combination with other antiretroviral agents for the management of Human Immunodeficiency Virus (HIV-1) infection in both adult and pediatric patients. This medication is utilized as part of a therapeutic regimen to address the chronic nature of the condition. It is employed in the management of HIV-1 infection in appropriate clinical settings, including individuals who have not previously received antiretroviral therapy (treatment-naïve) or those who are treatment-experienced, when combined with a boosting agent such as ritonavir or cobicistat, alongside other necessary HIV medications.

The primary benefit is that this therapy helps maintain health status and supports the overall management of the condition within an established care plan. This approach helps patients manage their infection.

“This therapy is associated with benefits that can support broader public health objectives when used as part of a comprehensive strategy.”


Quick Fact: Relief for Viral Load Management


Regulatory References

  1. European Medicines Agency (EMA) public assessment report

Eligibility and Restrictions for Use

Population Eligibility for Ddr (Dexlansoprazole)

The regulatory eligibility profile for Ddr is defined by specific contraindications, age limits, and requirements related to organ function and physiological states, according to official governmental regulatory documents.

Absolute Contraindications

Ddr is formally contraindicated in patients with a known hypersensitivity to dexlansoprazole or any component of the formulation. The medication must also not be used if the patient is concurrently taking rilpivirine-containing products, as this is a specific exclusion listed in the official labeling.

Age-Based Eligibility

Ddr is approved for use in adults and adolescents (12 to 17 years old). Safety and effectiveness have not been established for pediatric patients younger than 12 years of age, and use is generally not recommended in children under 2 years old.

Organ Function and Restricted Use

Eligibility is conditional based on liver health. The medication is not recommended for patients with Severe Hepatic Impairment (Child-Pugh Class C). For those with Moderate Hepatic Impairment (Child-Pugh Class B), a specific maximum daily dose limitation is required for certain uses. No dosage adjustment is necessary for patients with renal impairment.

Pregnancy and Lactation Status

Use during pregnancy is advised only if clearly needed. For nursing mothers, the use of Ddr requires a careful assessment of its importance against the potential risk to the infant, as excretion into human milk is unknown.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details the specific drug-drug and drug-substance interactions for dexlansoprazole. These interactions are categorized by the regulatory impact on systemic exposure or therapeutic effect of either Ddr or the co-administered product.

Classification Interacting Substances (Official Examples)
Formal Contraindication Rilpivirine (or rilpivirine-containing products)
Exposure Elevation Risk Methotrexate, Tacrolimus, Digoxin
Exposure Reduction Risk Atazanavir, Clopidogrel, Ketoconazole, Itraconazole, Iron Salts
Pharmacodynamic Risk Diuretics (risk of hypomagnesemia)

The major interaction mechanism is the alteration of gastric pH, which leads to reduced absorption and sub-therapeutic concentrations of many medicines that require an acidic environment for solubility, including Atazanavir and certain antifungals. This pH effect is the basis for the contraindication with Rilpivirine.

Additionally, Ddr is metabolized primarily by CYP enzymes CYP2C19 and CYP3A4. Agents that inhibit these enzymes (e.g., Fluvoxamine) can officially increase the systemic exposure of Ddr, while enzyme inducers (e.g., Rifampicin, St John’s wort) may reduce it.

Specific monitoring is required for anticoagulants like Warfarin due to documented changes in the International Normalized Ratio (INR). The official labeling requires a timing separation, as Sucralfate must be administered at least 1 hour after Ddr. Furthermore, treatment must be interrupted for a specified period (at least 5 days) before diagnostic Chromogranin A (CgA) measurements.

Mechanism of Action

Targeted Inhibition of Discoidin Domain Receptors (DDR1/2)

Ddr acts as an inhibitor targeting the intracellular tyrosine kinase domains of Discoidin Domain Receptor 1 (DDR1) and DDR2. This interaction prevents the autophosphorylation and activation of the receptors, which are normally triggered by the extracellular ligand, collagen. This foundational action modulates signaling at the cell-matrix interface by blocking the signal initiation.


Dampening of Tissue Remodeling Cascades

The blockage of DDR signaling suppresses downstream intracellular pathways, notably the activation of components like NF-κB, p38 MAPK, and the expression of Matrix Metalloproteinases (MMPs). This mechanistic cascade alters the cellular response to the surrounding matrix, resulting in a reduction of collagen degradation and subsequent matrix reorganization at the tissue level.


Physiological Shift via Modified Pathway Activity

By modulating these molecular and cellular processes, Ddr influences activity within targeted peripheral pathways. This limits the downstream effects of dysregulated extracellular matrix signaling and results in the reduced activity of pro-inflammatory and pro-proliferative signaling components within the affected tissue, leading to a shift in tissue integrity regulation.

Dosage and Administration Information

How to Use Ddr — Official Administration Guidelines

Ddr (dexlansoprazole) is an oral, delayed-release capsule intended to be taken once daily without regard to food. The official instructions detail precise dosing regimens and preparation requirements to ensure the capsule's Dual Delayed Release properties are maintained.


Standard Labeled Dosing Regimens (Adults and Children 12 Years)

Treatment Goal Recommended Dose Frequency & Duration
Healing of Erosive Esophagitis (EE) 60 mg Once daily for up to 8 weeks
Maintenance of Healed EE 30 mg Once daily (up to 6 months in adults)
Symptomatic Non-Erosive GERD 30 mg Once daily for 4 weeks

Administration and Preparation

The delayed-release capsule must be swallowed whole and must not be chewed, crushed, or broken.

Alternative Administration

  • The capsule may be opened, and the intact granules sprinkled onto one tablespoon of applesauce. This mixture must be swallowed immediately without chewing the granules.
  • Alternatively, the contents may be administered with water via an oral syringe or a nasogastric (NG) tube ( 16 French) following specific mixing instructions.

Population-Specific Dosing

  • Hepatic Impairment: For patients with moderate (Child-Pugh Class B) hepatic impairment, the recommended daily dose is a maximum of 30 mg. Use is not recommended for those with severe (Child-Pugh Class C) impairment.
  • Renal Impairment: No dosage adjustment is specified in the official labeling.

Missed Dose Rule: If a dose is missed, administer it as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Do not take two doses at once to make up for the missed dose.

Recent Clinical Evidence

Ddr: Recent Clinical Evidence

This section provides an overview of the clinical research conducted for Ddr, describing the focus of the studies, the populations involved, and the follow-up periods examined. This summary is intended to describe the available evidence, not to offer medical advice or treatment recommendations.


Research examining Esophageal Damage (Erosive Esophagitis)

Research evidence examining this condition comes primarily from short-term, double-blind, randomized controlled trials applied in research contexts examining adults and subsequently adolescents (aged 12 to 17 years). The key focus of this research examined rates of complete healing of esophageal erosions, which was measured objectively through endoscopy. The findings describe patterns observed in the studies related to the proportion of patients with complete healing following the short treatment course. However, long-term effects are not fully established regarding the stability of healing beyond the typical 8-week treatment period, and data for certain groups remain insufficient.


Research exploring Maintenance of Healed Esophagitis

Following initial research into healing, intermediate-term, placebo-controlled trials were conducted to explore the topic of maintenance in adults who had already achieved a healed state. The research explored outcomes related to the sustained maintenance of healed esophageal status and the monitoring of the return of episodic symptoms, such as heartburn. Studies report how symptoms evolved over follow-up periods that were typically up to six months for adults. A key limitation is that there is limited information for long-term outcomes for maintenance beyond this six-month period.


Research exploring Symptomatic Heartburn (Non-Erosive GERD)

For symptomatic heartburn in patients without visible erosions, evidence is derived from short-term, blinded, placebo-controlled trials applied in studies examining short-term symptom changes. The main outcomes research explored were patient-reported outcomes, focusing on measuring the frequency of heartburn-free periods. Long-term effects are not fully established regarding the management of this condition, as the primary trials were designed to research exploring short-term symptom changes over defined intervals of only four weeks, and comparative evidence is lacking for management over extended periods.


Current Research Gaps and Uncertainties

The existing body of research primarily focuses on short-term symptom changes and healing phases. Therefore, long-term effects are not fully established, particularly concerning the durability of maintaining healed status over many years. While evidence exists for adolescents, sample sizes were smaller compared to adult trials, and data for certain groups remain insufficient regarding the use of Ddr in complex patient populations. The evidence highlights what is known—and what is still uncertain—about this medication.

Key Studies & References

  1. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Ddr (FAQ)


Q: Is Ddr the same type of medicine as [similar drug name]? What's the difference?

Ddr is classified in official documents as a Proton Pump Inhibitor (PPI). The primary difference described in regulatory documents relates to its unique Dual Delayed Release (DDR) formulation. This design allows the medicine to be released in the body at two separate times, with a design intended to provide sustained release.


Q: How quickly am I supposed to feel Ddr working?

Studies and official information indicate that the process of acid suppression may begin within the first few hours after administration. For symptomatic relief, effects are often noted in clinical research within the initial 24 to 48 hours of starting the regimen. Full healing of conditions like erosive esophagitis, however, is examined over longer treatment periods.


Q: Is Ddr safe for older adults?

Clinical studies examining the use of Ddr in older adult patients (65 years and over) did not observe a difference in overall safety or efficacy compared to younger patients. However, official information also notes that the greater sensitivity of some older individuals cannot be ruled out.


Q: What should I do if a side effect seems severe?

Regulatory warnings require immediate contact with a healthcare provider if you experience symptoms of a serious adverse reaction. This requirement applies to severe symptoms, such as signs of a serious allergic reaction or indicators of kidney issues (acute interstitial nephritis).


Q: Are there foods or drinks I need to avoid while taking Ddr?

Official regulatory instructions specify that Ddr can be taken without regard to food. The labeling does not contain any specific food restrictions that apply to the general use of the medication.


Q: Is Ddr addictive?

Ddr is not listed as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies. The official labeling does not contain warnings regarding dependence or withdrawal potential.


Q: Has Ddr been around for a long time?

According to the official drug archives, Ddr (dexlansoprazole) was approved by the U.S. FDA in 2009. Information detailing the regulatory history and subsequent approvals is publicly available through the agency’s documentation.


Q: What is the source of the research supporting Ddr?

The research evidence supporting Ddr is compiled and documented in the official regulatory filings for the drug. This information can be found in the Clinical Studies section of documents like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).


Q: Does Ddr interact with birth control pills?

Official regulatory documents do not list an interaction with oral contraceptives. Dexlansoprazole is not known to alter the blood levels of common components of birth control pills.


Q: Does Ddr interact with blood pressure medicine?

Regulatory documents list an interaction with diuretics, which are often used for blood pressure management. This is due to a potential risk of developing low magnesium levels (hypomagnesemia). Other blood pressure medicines are not specifically included in the official drug interaction list.


Q: What happens if I stop taking Ddr suddenly?

The regulatory labeling does not describe specific withdrawal or rebound effects associated with abrupt cessation of the drug. However, the recurrence of the underlying symptoms that the medication was treating may occur after the regimen is stopped.


Q: Does Ddr make you feel dizzy?

According to official regulatory labeling, dizziness is listed as an infrequent or uncommon adverse reaction.


Q: Are there any genetic factors that affect how Ddr works?

Official labeling notes that Ddr is processed by the liver enzyme CYP2C19, which can be affected by genetic variability. Regulatory data indicate that individuals identified as poor metabolizers of this enzyme may show higher systemic exposure to the medication.


Q: Can Ddr affect my driving ability?

Official labeling notes that some patients may experience effects on the central nervous system, such as dizziness or headache. Due to the possibility of these effects, official cautions exist regarding performing activities that require full alertness.


Q: Is Ddr different in pill form versus liquid form?

The official product is a capsule containing granules. While regulatory instructions permit opening the capsule to mix the intact granules with applesauce or water for alternative administration, this uses the capsule contents and is not a separate liquid formulation.


Q: What does 'contraindication' mean for Ddr?

In the context of drug labeling, a contraindication describes a condition or circumstance where the use of the drug is excluded. For Ddr, this includes a known hypersensitivity to the drug and concurrent use with certain antiviral medications, as listed in official documents.


Q: Why is Ddr prescription-only?

Ddr is classified as a prescription-only medicine because official regulatory bodies mandate that its proper use requires the supervision of a licensed healthcare professional. This is a classification based on the nature of the drug and its intended effects.


Q: Can Ddr be taken with common pain relievers like ibuprofen?

Official regulatory documents do not list specific interactions with common nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.


Q: What is the risk of an allergic reaction to Ddr?

The regulatory safety summary states that serious allergic reactions, including hypersensitivity, are considered infrequent or rare adverse events. Hypersensitivity to the medication is listed as an absolute contraindication in official documents.


Q: How long until the full benefit of Ddr is seen?

The time needed to achieve the full therapeutic benefit depends on the specific condition being addressed. Clinical studies for healing erosive esophagitis, for instance, typically examine outcomes over a period of up to eight weeks, and maintenance studies track effects for up to six months.


Q: What is the significance of the FDA black box warning for Ddr?

Ddr does not carry an FDA black box warning, according to the official labeling. This type of warning is reserved by the U.S. Food and Drug Administration for drugs with specific serious or life-threatening risks.


Q: Is Ddr a controlled substance?

Ddr is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies.


Q: Does Ddr affect fertility in men or women?

Non-clinical animal studies have examined reproductive toxicology and showed no impairment of fertility in animal models at relevant doses. Human data regarding fertility is often limited in official regulatory documentation.


Q: Is it okay to take Ddr with vitamins?

Regulatory information notes that long-term use is associated with a risk of Vitamin B12 deficiency. However, there are no specific contraindications or required timing separations listed in official documents for most common multivitamin supplements.

How should Ddr be stored and disposed of?

Darunavir (DDR) must be stored under specific conditions to maintain product stability, as detailed in official regulatory documentation.

Official Storage and Handling

  • Temperature: Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). Temporary excursions between 15 C and 30 C (59 F and 86 F) are permitted.
  • Container: The medicine must be kept in the original container and the container must remain tightly closed to protect the product from moisture.
  • Child Safety: It is mandatory to keep Darunavir out of the reach of children.

Disposal Requirements

Disposal of unused or expired product must follow government guidelines. The preferred method is a drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance (like coffee grounds or dirt) and sealed in a container before being discarded in the household trash. Personal information must be removed from the original label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ddr found in:

A-Z Index: